The pharmaceutical industry is at a critical juncture, driven by the increasing integration of artificial intelligence (AI) in drug research and development (R&D). This transformation is exemplified by the rise of biomedical AI, with initiatives such as the inauguration of a dedicated institute in Vienna by the Austrian Academy of Sciences and the Boehringer Ingelheim Foundation. Major players like Sanofi are leveraging AI to optimize drug target discovery, while AI is also revolutionizing the manufacturing of cell and gene therapies. These advancements promise to shorten time-to-market and improve treatment efficacy, while posing regulatory and ethical challenges.
Débloquez l'Analyse Complète
Accédez instantanément à nos insights exclusifs générés par IA, basés sur l'agrégation de centaines de sources sectorielles.
